A Study of RO4917523 in Pediatric Patients With Fragile X Syndrome

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2013
This randomized, double-blind, placebo-controlled, parallel-arm study will evaluate the safety and exploratory efficacy and pharmacokinetics of RO4917523 in pediatric patients with fragile X syndrome. Patients will be randomized to receive one of 2 dose levels of RO4917523 or placebo orally daily for 12 weeks.
Epistemonikos ID: 8ec959253c34cc006f7a6716e4e38bf3406709a4
First added on: May 11, 2024